A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-13. Anything still debated is marked as such rather than presented as settled.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Some women complain of a "small penis" when the trim procedure is performed, owing to the un-addressed clitoral hood tissue and completely removed (amputated) labia minor. Most plastic surgeons do not perform this procedure, and instead favor the extended wedge approach, which is technically more demanding, but produces a more natural result and is able to create a natural and proportioned appearance to the vulva. Reconstructive procedures are often required after the trim (amputation) labiaplasty.
The term "wet market", which specifies markets that sell fresh produce and meat, includes a broad variety of markets. These markets can be categorized according to their ownership structure (privately owned, state-owned, or community-owned), scale (wholesale or retail), and produce (fruits, vegetables, slaughtered meat, or live animals). They can be further subcategorized based on whether the meat inventory originates from domesticated or wild animals. Traditional markets are typically housed in temporary sheds, open-air sites, or partially open commercial complexes, while modern ones are housed in buildings often equipped with improved ventilation, freezing, and refrigeration facilities.
=== Measuring methods for contents of cannabinoids === Measuring methods for cannabinoids are based on the extraction of fluids from the hemp plant. Research and studies conducted at the University of Wuppertal (Germany) have shown that extracts contain much less of the initial contents of the hemp plant present in the juice. Besides, with extracts there is a risk of residues of solvents. There are no specific measuring methods for the quantities of cannabinoids in hemp juice accepted by all states. The EU is working on the development of a commonly accepted procedure. An alternative procedure used for the extraction of fluids first filters and centrifuges the hemp juice. The findings however showed no traces of cannabinoids because the characteristic contents of the hemp plant solely can be found in the unfiltered hemp juice.
== Research == Both acute and chronic stress are under preliminary research for the potential to participate in insulin resistance. Experimental approaches for insulin resistance are under investigation, including stem cell-based therapies, extracellular vesicles such as exosomes, pharmacological combinations, and tissue-engineering platforms; however, these strategies remain primarily in the research stage and are not established standard treatments.
The mechanism of melatonin biosynthesis initiates with the hydroxylation of L-tryptophan, a process that requires the cofactor tetrahydrobiopterin (THB) to react with oxygen and the active site iron of tryptophan hydroxylase. Although the complete mechanism is not entirely understood, two main mechanisms have been proposed: The first mechanism involves a slow transfer of one electron from THB to molecular oxygen (O2), potentially producing a superoxide (O−2). This superoxide could then recombine with the THB radical to form 4a-peroxypterin. 4a-peroxypterin may either react with the active site iron (II) to create an iron-peroxypterin intermediate or directly transfer an oxygen atom to the iron, facilitating the hydroxylation of L-tryptophan. Alternatively, the second mechanism proposes that oxygen interacts with the active site iron (II) first, forming iron (III) superoxide. This molecule could then react with THB to form an iron-peroxypterin intermediate. Following the formation of iron (IV) oxide from the iron-peroxypterin intermediate, this oxide selectively attacks a double bond to yield a carbocation at the C5 position of the indole ring. A subsequent 1,2-shift of the hydrogen and the loss of one of the two hydrogen atoms on C5 would restore aromaticity, producing 5-hydroxy-L-tryptophan. The decarboxylation of 5-hydroxy-L-tryptophan to produce 5-hydroxytryptamine is then facilitated by a decarboxylase enzyme with pyridoxal phosphate (PLP) as a cofactor.
Sources: en.wikipedia.org
=== Benign prostatic hyperplasia === A meta-analysis found that tadalafil is an effective treatment for lower urinary tract symptoms due to benign prostatic hyperplasia and that such treatment had a low rate of adverse effects. Tadalafil is FDA-approved for males as a therapy to treat and prevent symptoms of benign prostatic hyperplasia, such as urinary urgency, hesitancy, weak stream, dribbling, and incontinence. Tadalafil was found to have similar benefits for lower urinary tract symptoms as the usually prescribed tamsulosin.
The three substrates of this enzyme are aromadendrin ((+)-dihydrokaempferol), reduced nicotinamide adenine dinucleotide phosphate (NADPH), and a proton. Its products are leucopelargonidin and oxidised NADP+. This enzyme is an oxidoreductase with the systematic name cis-3,4-leucopelargonidin:NADP+ 4-oxidoreductase. Other names in common use include dihydroflavanol 4-reductase (DFR), dihydromyricetin reductase, NADPH-dihydromyricetin reductase, and dihydroquercetin reductase. It participates in flavonoid biosynthesis.
When gunfights finally erupted outside and around the television studio, they were almost always the result of miscommunication. One such example is when a group of Patriotic Guardsmen took up a defensive position in a building close to the television centre on the 23rd. It has not been established who took the first shots at around 17:00, but a gunfight soon ensued with those in the television station returning fire onto the position of the Patriotic guards, according to an aid worker who had set up a first aid station at the side of the television station, and who said that, afterwards, the group of Patriotic Guardsmen would later deny that they had fired first. This is only one of many examples of gunfights between pro-revolution forces after the flight of Ceaușescu on the 22nd. Scenes of major gunfights during this period include the television, radio and telephone buildings, as well as Casa Scânteii (the nation's print media center, which serves a similar role today under the name of the "House of the Free Press", Casa Presei Libere) and the post office in the district of Drumul Taberei; Palace Square (site of the Central Committee building, but also of the Central University Library, the national art museum in the former Royal Palace, and the Ateneul Român (Romanian Athenaeum), Bucharest's leading concert hall); the university and the adjoining University Square (one of the city's main intersections); Otopeni and Băneasa airports; hospitals; and the Ministry of Defence.
Hypoglycemia is a condition that occurs when blood glucose levels decrease below normal, causing symptoms including anxiety, tremors, nausea, palpitations, confusion, and coma. Individuals with diabetes or other conditions that result in low blood sugar may carry glucose tablets, oral glucose gel, hard candy, or sugar packets to use when their blood sugar becomes too low. Severe low blood sugar can lead to confusion, coma, neurological damage and other potentially serious complications, making it unsafe to administer glucose by mouth. In these cases, dextrose (D-glucose) can be administered into a vein to quickly and directly raise blood glucose levels.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.